Peer-reviewed journal EuroIntervention is set to publish results from preclinical trials on a Xeltis aortic valve (AV). The data, currently available online, showed that Xeltis’ AV had a good acute hemodynamic performance, comparable to that of commercially available devices. In addition, the Xeltis AV demonstrated good competence immediately after implantation, with no cases of transvalvular regurgitation beyond mild.
“The initial data on the AV acute performance published in EuroIntervention set an important start for Xeltis’ aortic valve preclinical program,” commented Xeltis CTO Martijn Cox. “They support the potential of Endogenous Tissue Restoration (ETR) in the high-pressure side of the heart, which is very important given the growing number of patients that may require aortic valve intervention every year,” he added.
EuroIntervention is the official publication of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and is endorsed by The European Society of Cardiology (ESC). Insights on how ETR may help overcome the limitations of current heart valve replacement options have also recently been published in the journal.
